OTUD3 and breast cancer: Whereas miR-520h induced paclitaxel resistance in breast cancer MCF-7 cells by inhibiting the OTUD3/PTEN axis, co-treatment with miR-520h inhibitor and OTUD3 overexpression significantly enhanced the sensitivity of MCF-7 cells to paclitaxel [54].